← All trials
NCT00934154
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Mar 1, 2006
- Primary completion
- Sep 1, 2009
- Completion date
- Sep 1, 2012
- First posted
- —
- Last posted
- —
- Enrollment
- 122
- Arms / groups
- 2 / —
- Source
- AACT · pre-existing
Sponsors
- Erkim Ilac A.S.Lead sponsor
- Gazi UniversityOverall official - principal investigator
- University of AnkaraOverall official - principal investigator
- Erkim Ilac A.S.Sponsor investigator
- Turkish Society of HematologyCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.